Given the clinical challenge posed by the poor permeability of large-molecule agents across an intact BBB in HER2-positive BC brain metastases, emerging BBB-penetrating drug delivery technologies are actively being explored in clinical settings. This evidence concerns the gene ERBB2 and breast cancer.